Scientific and Clinical Foundations of Toxicology
This domain tests whether you can reason from first principles about how chemicals injure biological systems, and how that reasoning is evidenced. Questions ask you to interpret dose–response data, distinguish hazard from risk, choose the right metric (LD50, NOAEL, therapeutic index), and judge whether an effect in a patient or population is causally attributable to an exposure rather than to confounding.
Dose–response: what the numbers mean
- Graded responses (enzyme activity, receptor occupancy) are measured within one system; quantal responses (death, tumour) are scored all-or-none across a population and generate the familiar sigmoid curve.
- The threshold is the dose below which the population response is indistinguishable from background. Hormesis (low-dose stimulation, high-dose inhibition) exists but is rarely used as a regulatory basis.
- LD50 and LC50 describe population potency, not a lethal dose for any individual. Curve slope determines how many subjects lie near the median: two agents with identical LD50 can differ greatly in the fraction harmed at 0.5 × LD50.
- Potency is not hazard. A very potent agent with negligible exposure may pose far less risk than a weakly potent one with ubiquitous exposure.
Comparing doses across species and routes
mg/kg is a first approximation; body-surface-area scaling is preferred for human equivalent dose using Km factors (mouse 3, rat 6, human 37): HED = animal mg/kg × Km_animal / Km_human. Route changes bioavailability substantially, and inhaled LC50 values given in ppm must be converted to mg/m3 (ppm × MW / 24.45).
Judging causation
Hill criteria (temporality, strength, consistency, biological plausibility, coherence, experiment, specificity, dose–response, analogy) are aids, not a checklist - temporality is the only near-necessary one. Dechallenge, rechallenge and dose plausibility carry real weight.
Worked example. A rat oral LD50 is 50 mg/kg (MW 200) and a 70 kg worker's intake is estimated at 200 mg/day. Naive extrapolation gives 50 × 70 = 3,500 mg as a human lethal dose. Surface-area scaling gives 50 × 6/37 ≈ 8.1 mg/kg, or about 570 mg. Intake is roughly one-third of that scaled median, so the margin is narrow but the LD50 does not quantify this individual's risk. The correct next step is biomonitoring, not arithmetic reassurance.
Traps that cost marks
- Treating LD50 as a threshold in a single patient.
- Using NOAEL as a safe level rather than the point of departure for uncertainty factors.
- Ignoring curve slope or route when comparing agents.
- Seeking a threshold for genotoxic carcinogens, where default risk assessment is low-dose linear.